NYSE:SYK - Stryker Stock Price, Forecast & News

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker announced a quarterly dividend on Friday, February 7th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.575 per share on Thursday, April 30th. This represents a $2.30 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Monday, March 30th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) posted its quarterly earnings results on Tuesday, January, 28th. The medical technology company reported $2.49 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $2.46 by $0.03. The medical technology company earned $4.13 billion during the quarter, compared to analyst estimates of $4.11 billion. Stryker had a return on equity of 25.75% and a net margin of 13.99%. Stryker's revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.18 earnings per share. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Stryker.

Stryker issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $9.00-9.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.04.

22 brokerages have issued 1 year price targets for Stryker's stock. Their forecasts range from $192.00 to $250.00. On average, they expect Stryker's share price to reach $229.10 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Stryker.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.

News stories about SYK stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stryker earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Stryker.

Stryker saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,910,000 shares, an increase of 10.8% from the December 31st total of 3,530,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 2.9 days. Approximately 1.1% of the shares of the stock are sold short. View Stryker's Current Options Chain.

Some companies that are related to Stryker include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Visa (V), Home Depot (HD), Medtronic (MDT), AbbVie (ABBV), Boeing (BA), NVIDIA (NVDA), Alibaba Group (BABA) and Abbott Laboratories (ABT).

Stryker's stock is owned by many different of institutional and retail investors. Top institutional investors include Greenleaf Trust (5.74%), State Street Corp (3.66%), FMR LLC (2.91%), Capital Research Global Investors (2.54%), Bank of New York Mellon Corp (1.86%) and Franklin Resources Inc. (1.52%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, David Floyd, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Institutional Ownership Trends for Stryker.

SYK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Capital International Investors, Alliancebernstein L.P., Massachusetts Financial Services Co. MA, Janus Henderson Group PLC, Jensen Investment Management Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

SYK stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., CWS Financial Advisors LLC, PGGM Investments, State Street Corp, Geode Capital Management LLC, Schroder Investment Management Group and GQG Partners LLC. View Insider Buying and Selling for Stryker.

Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYK stock can currently be purchased for approximately $223.92.

Stryker has a market capitalization of $83.88 billion and generates $14.88 billion in revenue each year. The medical technology company earns $2.08 billion in net income (profit) each year or $8.26 on an earnings per share basis. Stryker employs 40,000 workers across the globe.View Additional Information About Stryker.

The official website for Stryker is http://www.strykercorp.com/.

Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]